GHRH/GHS-R Dual Secretagogue Blend
CJC-1295 (No DAC) + Ipamorelin
Synergistic blend of CJC-1295 (No DAC) and Ipamorelin studied for amplified pulsatile GH release via dual GHRH and ghrelin receptor pathway activation.
Select Size
Tested by: Intertek Pharmaceutical Services · Batch: VRC-CJI-2407 · Jul 2026
About CJC-1295 (No DAC) + Ipamorelin
This research blend combines CJC-1295 without DAC (Modified GRF 1-29), a stabilized GHRH analog, with Ipamorelin, a selective GHS-R agonist. The two peptides act on distinct receptor pathways — GHRH receptors and ghrelin/GHS-R receptors respectively — producing synergistic, amplified pulsatile GH release in preclinical models. The combination is widely studied in GH axis research for its ability to maximize GH secretion while preserving physiological pulsatility and minimizing off-target effects on cortisol and prolactin.
Research Areas
Technical Specifications
Molecular Weight
Variable (dual-peptide blend)
Amino Acid Sequence
CJC-1295 (No DAC): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ | Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Storage
Lyophilized: −20°C, stable 24 months. Reconstituted: 4°C, use within 28 days.
Solubility
Soluble in bacteriostatic water at ≥1 mg/mL
For Research Purposes Only. CJC-1295 (No DAC) + Ipamorelin is sold exclusively for in vitro laboratory research. Not for human consumption, diagnostic, therapeutic, or veterinary use. See our Research Use Disclaimer.